Why Be Optimistic if the Payers Are Cautious?

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

<p>U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the market.  The latest company to reiterate this view is the senior management of generic industry leader Teva Pharmaceutical (TEVA:US) which just conducted an investor day focused on its generics division.</p><p>We continue to think that Celltrion's forecast of end market sales of US$1.7 billion in 2017 for its Remicade biosimilar Inflectra (Remsima elsewhere)…</p>

U.S. healthcare industry leaders from across the spectrum of industry segments continue to downplay the near-term adoption of biosimilars in the market.  The latest company to reiterate this view is the senior management of generic industry leader Teva Pharmaceutical (TEVA:US) which just conducted an investor day focused on its generics division.We continue to think that Celltrion's forecast of end market sales of US$1.7 billion in 2017 for its Remicade biosimilar Inflectra (Remsima elsewhere)…

Celltrion Inc

More Harsh Reality from Teva